Compare SGU & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGU | CMPX |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.3M | 371.0M |
| IPO Year | 1997 | 2020 |
| Metric | SGU | CMPX |
|---|---|---|
| Price | $12.88 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 22.1K | ★ 3.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.37 | $1.61 |
| 52 Week High | $13.53 | $6.88 |
| Indicator | SGU | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 53.24 |
| Support Level | $12.33 | $1.88 |
| Resistance Level | $12.85 | $2.47 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 73.89 | 84.85 |
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.